Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 178

1.

Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial.

Baptista T, Rangel N, Fernández V, Carrizo E, El Fakih Y, Uzcátegui E, Galeazzi T, Gutiérrez MA, Servigna M, Dávila A, Uzcátegui M, Serrano A, Connell L, Beaulieu S, de Baptista EA.

Schizophr Res. 2007 Jul;93(1-3):99-108. Epub 2007 May 8.

PMID:
17490862
2.

Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial.

Baptista T, Martínez J, Lacruz A, Rangel N, Beaulieu S, Serrano A, Arapé Y, Martinez M, de Mendoza S, Teneud L, Hernández L.

Can J Psychiatry. 2006 Mar;51(3):192-6.

PMID:
16618011
3.

Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study.

Carrizo E, Fernández V, Connell L, Sandia I, Prieto D, Mogollón J, Valbuena D, Fernández I, de Baptista EA, Baptista T.

Schizophr Res. 2009 Aug;113(1):19-26. doi: 10.1016/j.schres.2009.05.007. Epub 2009 Jun 9. Erratum in: Schizophr Res. 2009 Nov;115(1):96.

PMID:
19515536
4.

Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.

Wu RR, Zhao JP, Guo XF, He YQ, Fang MS, Guo WB, Chen JD, Li LH.

Am J Psychiatry. 2008 Mar;165(3):352-8. doi: 10.1176/appi.ajp.2007.07010079. Epub 2008 Feb 1.

PMID:
18245179
5.

Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin.

Baptista T, Sandia I, Lacruz A, Rangel N, de Mendoza S, Beaulieu S, Contreras Q, Galeazzi T, Vargas D.

Int Clin Psychopharmacol. 2007 Mar;22(2):69-76.

PMID:
17293706
6.

Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial.

Baptista T, Rangel N, El Fakih Y, Uzcátegui E, Galeazzi T, Beaulieu S, Araujo de Baptista E.

Pharmacopsychiatry. 2009 Jan;42(1):14-9. doi: 10.1055/s-0028-1085438. Epub 2009 Jan 19.

PMID:
19153941
7.

A Naturalistic Randomized Placebo-Controlled Trial of Extended-Release Metformin to Prevent Weight Gain Associated With Olanzapine in a US Community-Dwelling Population.

Rado J, von Ammon Cavanaugh S.

J Clin Psychopharmacol. 2016 Apr;36(2):163-8. doi: 10.1097/JCP.0000000000000469.

PMID:
26872112
8.

Effects of a combination of recombinant human growth hormone with metformin on glucose metabolism and body composition in patients with metabolic syndrome.

Herrmann BL, Berg C, Vogel E, Nowak T, Renzing-Koehler K, Mann K, Saller B.

Horm Metab Res. 2004 Jan;36(1):54-61.

PMID:
14983408
9.

Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study.

Wu RR, Jin H, Gao K, Twamley EW, Ou JJ, Shao P, Wang J, Guo XF, Davis JM, Chan PK, Zhao JP.

Am J Psychiatry. 2012 Aug;169(8):813-21. doi: 10.1176/appi.ajp.2012.11091432.

PMID:
22711171
10.

Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial.

Narula PK, Rehan HS, Unni KE, Gupta N.

Schizophr Res. 2010 May;118(1-3):218-23. doi: 10.1016/j.schres.2010.02.001. Epub 2010 Mar 7.

PMID:
20207521
11.

Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study.

Smith RC, Lindenmayer JP, Davis JM, Kelly E, Viviano TF, Cornwell J, Hu Q, Khan A, Vaidhyanathaswamy S.

J Clin Psychiatry. 2009 Nov;70(11):1501-13. doi: 10.4088/JCP.08m04446yel. Epub 2009 Oct 6.

PMID:
19814947
12.

Metformin for treatment of antipsychotic-induced weight gain in a South Asian population with schizophrenia or schizoaffective disorder: A double blind, randomized, placebo controlled study.

de Silva VA, Dayabandara M, Wijesundara H, Henegama T, Gunewardena H, Suraweera C, Hanwella R.

J Psychopharmacol. 2015 Dec;29(12):1255-61. doi: 10.1177/0269881115613519. Epub 2015 Oct 28.

PMID:
26510448
13.

Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia.

Hosojima H, Togo T, Odawara T, Hasegawa K, Miura S, Kato Y, Kanai A, Kase A, Uchikado H, Hirayasu Y.

J Psychopharmacol. 2006 Jan;20(1):75-9. Epub 2005 Oct 4.

PMID:
16204328
14.

A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients.

Hu S, Yao M, Peterson BS, Xu D, Hu J, Tang J, Fan B, Liao Z, Yuan T, Li Y, Yue W, Wei N, Zhou W, Huang M, Xu Y.

Psychopharmacology (Berl). 2013 Nov;230(1):3-13. doi: 10.1007/s00213-013-3073-1. Epub 2013 Apr 5.

PMID:
23559220
15.

Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.

Wu RR, Zhao JP, Jin H, Shao P, Fang MS, Guo XF, He YQ, Liu YJ, Chen JD, Li LH.

JAMA. 2008 Jan 9;299(2):185-93. doi: 10.1001/jama.2007.56-b.

PMID:
18182600
16.

Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses.

Melkersson KI, Hulting AL, Brismar KE.

J Clin Psychiatry. 2000 Oct;61(10):742-9.

PMID:
11078035
17.
18.

Polymorphisms of the LEP- and LEPR genes, metabolic profile after prolonged clozapine administration and response to the antidiabetic metformin.

Fernández E, Carrizo E, Fernández V, Connell L, Sandia I, Prieto D, Mogollón J, Valbuena D, Fernández I, de Baptista EA, Baptista T.

Schizophr Res. 2010 Aug;121(1-3):213-7. doi: 10.1016/j.schres.2010.06.001. Epub 2010 Jun 29.

PMID:
20591628
19.

Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder.

Kemp DE, Zhao J, Cazorla P, Landbloom RP, Mackle M, Snow-Adami L, Szegedi A.

J Clin Psychiatry. 2014 Mar;75(3):238-45. doi: 10.4088/JCP.12m08271.

PMID:
24499969
20.

Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine.

Chen CH, Chiu CC, Huang MC, Wu TH, Liu HC, Lu ML.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 May 15;32(4):925-31. Epub 2007 Nov 17.

PMID:
18082302

Supplemental Content

Support Center